Intranasal anthrax vaccine: BlueWillow Receives FDA Clearance to Begin Phase 1 Study

BlueWillow Biologics(R), a clinical-stage biopharmaceutical company, announced this week that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for BW-1010, the company's next-generation anthrax vaccine candidate. The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy ["]

The post Intranasal anthrax vaccine: BlueWillow Receives FDA Clearance to Begin Phase 1 Study appeared first on Outbreak News Today.